Payment overview · 2025
General Payments
$434.12
19 reported records · 7 companies
Healthcare provider profile · identity verified
Jenean White, MD
Allopathic & Osteopathic Physicians|Family Medicine · HARTWELL, GA · NPI 1922049204
Verified facts
What the public records show
CMS Open Payments records show Jenean White, MD received $434.12 in general payments during 2025 across 19 reported records.
Lilly USA, LLC accounted for 35.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Quviviq, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
IDORSIA PHARMACEUTICALS US INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUVIVIQ as an associated drug or biological on 2281 records involving 1911 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Quviviq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $154.09 | 35.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $100.06 | 23.1% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.95 | 13.8% | 3 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $41.97 | 9.7% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $33.17 | 7.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.88 | 7.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.00 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $434.12 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $135.37 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.60 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $59.95 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.09 | 3 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $41.97 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.46 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.46 | 2 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $33.17 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 84 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Quviviq quviviq |
2025 | Quviviq | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| IDORSIA PHARMACEUTICALS US INC Exact reporting entity; no affiliate inference |
2025 | QUVIVIQ open payments reported associated product |
CMS Open Payments — General Payments 2281 supporting records · 1911 recipient NPIs · example record 1243392023 |
Quviviq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 48 |
| Atorvastatin Calcium | Atorvastatin Calcium | 160 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 30 |
| Clonazepam | Clonazepam | 118 | 18 |
| Tramadol Hcl | Tramadol Hcl | 118 | 25 |
| Alprazolam | Alprazolam | 105 | 17 |
| Carvedilol | Carvedilol | 105 | 24 |
| Gabapentin | Gabapentin | 105 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 99 | 34 |
| Montelukast Sodium | Montelukast Sodium | 87 | 22 |
| Mounjaro | Tirzepatide | 84 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 25 |
| Omeprazole | Omeprazole | 82 | 26 |
| Ozempic | Semaglutide | 72 | suppressed |
| Losartan Potassium | Losartan Potassium | 69 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 24 |
| Furosemide | Furosemide | 67 | 20 |
| Famotidine | Famotidine | 65 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 12 |
| Trazodone Hcl | Trazodone Hcl | 59 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 16 |
| Alendronate Sodium | Alendronate Sodium | 57 | 17 |
| Sertraline Hcl | Sertraline Hcl | 56 | 13 |
| Clonidine Hcl | Clonidine Hcl | 53 | 16 |
| Lorazepam | Lorazepam | 49 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 49 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 11 |
| Linzess | Linaclotide | 46 | 12 |
| Metformin Hcl | Metformin Hcl | 46 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 16 |
| Estradiol | Estradiol | 44 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 13 |
| Donepezil Hcl | Donepezil Hcl | 42 | 13 |
| Lisinopril | Lisinopril | 41 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 20 |
| Potassium Chloride | Potassium Chloride | 38 | 12 |
| Meloxicam | Meloxicam | 37 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 23 |
| Allopurinol | Allopurinol | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Trulance | Plecanatide | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 17 |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Prednisone | Prednisone | 16 | 13 |
| Rybelsus | Semaglutide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $434.12 · 19 records | Lilly USA, LLC | AIRSUPRA, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), MOUNJARO, Ozempic, QULIPTA, Quviviq, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error